ANDA 217517, held by Teva Pharmaceuticals. Pazopanib Hydrochloride.
As of Nov 22, 2026, ANDA 217517 (Pazopanib Hydrochloride), held by Teva Pharmaceuticals, was first approved by FDA on Oct 19, 2023, with 0 approved supplements and 0 published complete response letters.
Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: advanced renal cell carcinoma (RCC). advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitations of Use: The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. 1.1 Renal Cell Carcinoma Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma (RCC). 1.2 Soft Tissue Sarcoma Pazopanib tablets are indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 19, 2023 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Pazopanib HydrochlorideEQ 200MG BASE · tablet;oral | Pazopanib Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters